EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

A Model for Predicting Clinically Significant Prostate Cancer Using Prostate MRI and Risk Factors

Ronilda Lacson, Arya Haj-Mirzaian, Kristine Burk, Daniel I Glazer, Sachin Naik, Ramin Khorasani, Adam S Kibel

Journal of the American College of Radiology · 2024

DOI: 10.1016/j.jacr.2024.02.035 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of the American College of Radiology, 2024. Verfasst von Ronilda Lacson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Associate Director, Cent…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS, AHRQ.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The aim of this study was to develop and validate a predictive model for clinically significant prostate cancer (csPCa) using prostate MRI and patient risk factors. METHODS: In total, 960 men who underwent MRI from 2015 to 2019 and biopsy either 6 months before or 6 months after MRI were identified. Men diagnosed with csPCa were identified, and csPCa risk was modeled using known patient factors (age, race, and prostate-specific antigen [PSA] level) and prostate MRI findings (location, Prostate Imaging Reporting and Data System score, extraprostatic extension, dominant lesion size, and PSA density). csPCa was defined as Gleason score sum ≥ 7. Using a derivation cohort, a multivariable logistic regression model and a point-based scoring system were developed to predict csPCa. Discrimination and calibration were assessed in a separate independent validation cohort. RESULTS: Among 960 MRI reports, 552 (57.5%) were from men diagnosed with csPCa. Using the derivation cohort (n = 632), variables that predicted csPCa were Prostate Imaging Reporting and Data System scores of 4 and 5, the presence of extraprostatic extension, and elevated PSA density. Evaluation using the validation cohort (n = 328) resulted in an area under the curve of 0.77, with adequate calibration (Hosmer-Lemeshow P = .58). At a risk threshold of >2 points, the model identified csPCa with sensitivity of 98.4% and negative predictive value of 78.6% but prevented only 4.3% potential biopsies (0-2 points; 14 of 328). At a higher threshold of >5 points, the model identified csPCa with sensitivity of 89.5% and negative predictive value of 70.1% and avoided 20.4% of biopsies (0-5 points; 67 of 328). CONCLUSIONS: The point-based model reported here can potentially identify a vast majority of men at risk for csPCa, while avoiding biopsy in about 1 in 5 men with elevated PSA levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMagnetic Resonance ImagingMaleHumansMiddle AgedRisk FactorsAgedRisk AssessmentPredictive Value of TestsNeoplasm GradingProstate-Specific AntigenRetrospective StudiesBiopsy

Stichwörter der Autor:innen

Prostate cancerpredictive modelpredictive value of testingprostate MRIprostate biopsy

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Associate Director, Center for Evidence-Based Imaging, Brigham and Women's Hospital, Boston, M…
  • Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
  • Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Quality and Patient Safety Officer, Mass General Brigham, Boston, Massachusetts.
  • Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Medical Director of CT and Director, Cross-Sectional Interventional Radiology, Department of R…
  • Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Vice Chair, Radiology Quality and Safety, Mass General Brigham, Boston, Massachusetts; and Vic…
  • Harvard Medical School, Boston, Massachusetts; Department of Surgery and Chair, Department of Urology, Brigham and Women's Hospital, Boston, Massachusetts.

Förderung

  • AHRQ HHS
  • AHRQ

Zitieren

APA

Lacson, R., Haj-Mirzaian, A., Burk, K., Glazer, D. I., Naik, S., Khorasani, R., & Kibel, A. S. (2024). A Model for Predicting Clinically Significant Prostate Cancer Using Prostate MRI and Risk Factors. Journal of the American College of Radiology. https://doi.org/10.1016/j.jacr.2024.02.035

Vancouver

Lacson R, Haj-Mirzaian A, Burk K, Glazer DI, Naik S, Khorasani R, et al. A Model for Predicting Clinically Significant Prostate Cancer Using Prostate MRI and Risk Factors. Journal of the American College of Radiology. 2024. doi:10.1016/j.jacr.2024.02.035

BibTeX
@article{Lacson2024,
  author = {Lacson, Ronilda and Haj-Mirzaian, Arya and Burk, Kristine and Glazer, Daniel I and Naik, Sachin and Khorasani, Ramin and Kibel, Adam S},
  title = {A Model for Predicting Clinically Significant Prostate Cancer Using Prostate MRI and Risk Factors},
  journal = {Journal of the American College of Radiology},
  year = {2024},
  doi = {10.1016/j.jacr.2024.02.035}
}
Kostenlos starten →